deltatrials

Plaque psoriasis Trials in Katowice, Poland

Conditions / Plaque psoriasis / Katowice, Poland

Plaque psoriasis has been the subject of sustained clinical investigation across multiple research sites.

20 total trials for this combination

Showing top 10 of 20 trials

Trials

NCT ID Title Status Phase
NCT06550076 A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis ACTIVE_NOT_RECRUITING PHASE3
NCT06108544 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period COMPLETED PHASE3
NCT06088043 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment COMPLETED PHASE3
NCT07116967 Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) RECRUITING PHASE3
NCT06588738 A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 ACTIVE_NOT_RECRUITING PHASE3
NCT02346240 Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) COMPLETED PHASE3
NCT01708629 Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects TERMINATED PHASE3
NCT06586112 A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis ACTIVE_NOT_RECRUITING PHASE3
NCT06934226 A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis ACTIVE_NOT_RECRUITING PHASE3
NCT06846541 Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis ACTIVE_NOT_RECRUITING PHASE3

Related Pages